HIF-1α deficiency perturbs T and B cell functions

Current Pharmaceutical Design

Volumn 9, Issue 23, 2003, Pages 1827-1832

  Kojima, Hidefumi ^a   Sitkovsky, Michail V ^b   Cascalho, Marilia ^c  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c MAYO CLINIC   (United States)

Author keywords

B lymphocyte; HIF 1 ; Lymphocyte development; T lymphocyte

Indexed keywords

AUTOANTIBODY; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN;

B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW CELL; CELL MATURATION; CELLULAR IMMUNODEFICIENCY; CYTOTOXIC T LYMPHOCYTE; DNA DAMAGE; EMBRYO DEVELOPMENT; FETUS; GENETIC RECOMBINATION; HUMORAL IMMUNE DEFICIENCY; HYPOXIA; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MORPHOGENESIS; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES; TRANSCRIPTION FACTORS;

EID: 0043180527     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454388     Document Type: Review

References (50)

1. Westermann J, Bode U. Distribution of activated T cells migrating through the body: a matter of life and death. Immunol Today 1999; 20: 302-6.
2. Caldwell CC, Kojima H, Lukashev D, Armstrong J, Farber M, Apasov SG, et al. Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol 2001; 167: 6140-9.
3. Loeffler DA, Keng PC, Baggs RB, Lord EM. Lymphocytic infiltration and cytotoxicity under hypoxic conditions in the EMT6 mouse mammary tumor. Int J Cancer 1990; 45: 462-7.
4. Dewhirst MW. Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol 1998; 8: 143-50.
5. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998; 18: 555-9.
6. Van Belle H, Goossens F, Wynants J. Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia. Am J Physiol 1987; 252: H886-93.
7. Matherne GP, Headrick JP, Coleman SD, Berne RM. Interstitial transudate purines in normoxic and hypoxic immature and mature rabbit hearts. Pediatr Res 1990; 28: 348-53.
8. Vaupel PW, Frinak S, Bicher HI. Heterogeneous oxygen partial pressure and pH distribution in C3H mouse mammary adenocarcinoma. Cancer Res 1981; 41: 2008-13.
9. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49: 6449-65.
10. Hoskin DW, Reynolds T, Blay J. Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours. Int J Cancer 1994; 59: 854-5.
11. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230-7.
12. Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 1998; 8: 588-94.
13. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15: 551-78.
14. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88: 1474-80.
15. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92: 5510-4.
16. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998; 95: 7987-92.
17. Salceda S, Caro J. Hypoxia-indUcible factor alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997; 272: 22642-7.
18. Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, Ratcliffe PJ, Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem 1997; 272: 11205-14.
19. Srinivas V, Zhang LP, Zhu XH, Caro J. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. Biochem Biophys Res Commun 1999; 260: 557-61.
20. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 1999; 274: 6519-25.
21. Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci U S A 2000; 97: 4748-53.
22. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-5.
23. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464-8.
24. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-72.
25. Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 2002; 417: 975-8.
26. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002; 16: 1151-62.
27. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12: 149-62.
28. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998; 17: 3005-15.
29. Kotch LE, Iyer NV, Laughner E, Semenza GL. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF, deficiency but with mesenchymal cell death. Dev Biol 1999; 209: 254-67.
30. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-90.
31. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest 1999; 103: 691-6.
32. Shimoda LA, Manalo DJ, Sham JS, Semenza GL, Sylvester JT. Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. Am J Physiol Lung Cell Mol Physiol 2001; 281: L202-8.
33. Chen J, Lansford R, Stewart V, Young F, Alt FW. RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development. Proc Natl Acad Sci U S A 1993; 90: 4528-32.
34. Kojima H, Gu H, Nomura S, Caldwell CC, Kobata T, Carmeliet P, et al. Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha -deficient chimeric mice. Proc Natl Acad Sci U S A 2002; 99: 2170-4.
35. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V. Mendelsohn M, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992; 68: 855-67.
36. Sebzda E, Mariathasan S, Ohteki T, Jones R, Bachmann MF, Ohashi PS. Selection of the T cell repertoire. Annu Rev Immunol 1999; 17: 829-74.
37. Lukashev D, Caldwell C, Ohta A, Chen P, Sitkovsky M. Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes. J Biol Chem 2001: 276: 48754-63.
38. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol 2001; 19: 595-621.
39. Chukwuocha RU, Nadel B, Feeney AJ. Analysis of homology-directed recombination in VDJ junctions from cytoplasmic Ig- pre-B cells of newborn mice. J Immunol 1995; 154: 1246-55.
40. Hao Z, Rajewsky K. Homeostasis of peripheral B cells in the absence of B cell influx from the bone marrow. J Exp Med 2001; 194: 1151-64.
41. Carvalho TL, Mota-Santos T, Cumano A, Demengeot J, Vieira P. Arrested B lymphopoiesis and persistence of activated B cells in adult interleukin 7(-/)- mice. J Exp Med 2001; 194: 1141-50.
42. Seegal BC, Accinni L, Andres GA, Beiser SM, Christian CL, Erlanger BF, et al. Immunologic studies of autoimmune disease in NZB-NZW F1 mice. I. Binding or fluorescein-labeled antinucleoside antibodies in lesions of lupus-like nephritis. J Exp Med 1969; 130: 203-16.
43. Knight JG, Adams DD. Three genes for lupus nephritis in NZB x NZW mice. J Exp Med 1978; 147: 1653-60.
44. Drake CG, Rozzo SJ, Vyse TJ, Palmer E, Kotzin BL. Genetic contributions to lupus-like disease in (NZB × NZW)F1 mice. Immunol Rev 1995; 144: 51-74.
45. Monneaux F, Dumortier H, Steiner G, Briand JP, Muller S. Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(1pr) and (NZB x NZW)F(1) lupus mice. Int Immunol 2001; 13: 1155-63.
46. Roths JB, Murphy ED. Eicher EM. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 1984: 159: 1-20.
47. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9: 243-69.
48. Alvarez D, Wiley RE, Jordana M. Cytokine therapeutics for asthma: an appraisal of current evidence and future prospects. Curr Pharm Des 2001; 7(11): 1059-81.
49. Gottlieb D. Cytokine manipulation of the immune response in the treatment of human acute leukaemia. Curr Pharm Des 2002; 8(5): 419-31.
50. Xing Z. The hunt for new tuberculosis vaccines: anti-TB immunity and rational design of vaccines. Curr Pharm Des 2001; 7(11): 1015-37.